In silico docking of COX-2 inhibitors to assess anti-metastatic potential in colorectal cancer (1)
Date and time is TBD
|On Going Project
Colorectal cancer remains a major cause of cancer-related mortality worldwide, with metastasis being the principal cause of poor prognosis. Cyclooxygenase-2 (COX-2), an enzyme involved in inflammation, is often overexpressed in colorectal tumors and has been implicated in cancer progression.
Time & Location
Date and time is TBD
On Going Project
About the event
🔍 Background:
Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally. Its progression to metastasis, particularly to the liver and lungs, significantly reduces survival rates. COX-2 plays a pivotal role in tumorigenesis by promoting angiogenesis, suppressing apoptosis, and enhancing the invasive capabilities of cancer cells. Hence, targeting COX-2 has emerged as a promising strategy to inhibit tumor growth and metastasis.
🧪 Scientific Rationale:
COX-2 inhibitors (e.g., celecoxib, etoricoxib) have shown anti-inflammatory and anticancer properties. However, their role in inhibiting metastasis specifically in CRC requires further elucidation. Molecular docking allows the prediction of interactions between COX-2 and potential inhibitory ligands, helping to identify candidates that could suppress pro-metastatic pathways.
💻 Methodology (Overview):
Target Protein Preparation: Retrieve and prepare 3D structure of COX-2 from Protein Data Bank (PDB).